Research Center: Medcorps
Locations: 100 Kings Way East, Suite D1 Sewell, NJ 08080; 222 New Road #201 Linwood, NJ 08221; 211 South Main St #203 Cape May Court House, NJ 08210
Lead Researcher: Dr. Allen Silvey
IRB: This study has been reviewed and approved by an institutional review board

Did you know that early detection of lung cancer can save lives? Lung cancer remains one of the most challenging and deadly diseases worldwide, and it is often diagnosed at advanced stages when treatment options are limited. Early detection is a critical factor in improving patient outcomes and reducing mortality rates associated with this formidable disease.

To address this pressing need, researchers from Medcorps are conducting a study to support the development of a blood test to detect of lung cancer at screening for widespread use among high-risk individuals. Help advance medical research by contributing to the development of groundbreaking technology with the potential to benefit many people in the future. Join this new research study!

• Participants will help advance lung cancer detection research.
• Participants will be compensated up to $75 for participating in this study.
• Compensation will only be provided to eligible participants who complete the study blood draws.
• Participants will be contributing valuable information that may benefit those with lung cancer in the future.

• If you decide to participate in the study and later feel that you no longer wish to be part of it, you can withdraw at any time.
• Any information that you provide will be kept strictly confidential, except as required by law.
• Qualified health professionals will monitor your health as it relates to the study.

• Men and women aged 55-75 years old who are currently undergoing or intending to undergo LDCT for lung cancer screening
• Must have an increased risk of lung cancer defined by having at least 25-pack-year smoking history and must currently smoke or have quit within the past 15 years
• Must not have history of any malignancy (subjects who have undergone surgical removal of skin squamous cell cancer may be enrolled provided the procedure was completed at least 12 months prior to the date of provision of informed consent for the study)
• Must not have any conditions that may limit their life expectancy
• Must not be taking anti-neoplastic or disease-modifying anti-rheumatic medications
• Must not be receiving treatments for pneumonia
• Must not have any major physical trauma (e.g. disruption of tissue, surgery, organ transplant, blood product transfusion) within the 30 days leading up to the provision of informed consent
• Must not be participating in another clinical study in which an experimental medication has been administered or may be administered within the next 30 days
• Must be willing and able to provide blood samples
• Must be able to attend 2 or more study visits at the research site over approximately 2 years. Please note that this study is being conducted in three different locations across New Jersey – eligible participants will be able to come to whichever practice location is nearest to them.

The study team will explain the research in its entirety but some details are:

• Participants will be asked about their health and medically relevant social history, including past and present diseases, surgeries, drug/substance use, and conditions for which they take medications.
• Participants will need to complete a Lung Health Questionnaire covering various aspects of their history, education, smoking, and lung cancer risk factors. A routine low-dose CT scan (LDCT) of the chest will be scheduled within 90 days of their blood collection. This scan is part of their regular healthcare and not specific to the study. Subsequent diagnostic follow-up to your LDCT scan will be performed as standard of care procedures directed by your physician.
• The study may involve additional health information requests or medical record checks based on each participant’s CT scan results. A study team member may contact you to retrieve results

Medcorps
MedCorps’ expert team of pulmonologists, nurse practitioners, and physician assistants is dedicated to providing personalized care for respiratory conditions. They specialize in diagnosing and managing various pulmonary disorders, emphasizing patient education, proactive disease prevention, and the latest medical advancements. Whether it’s asthma, COPD, sleep apnea, or other respiratory concerns, their compassionate team aims for optimal lung health.
Additionally, they conduct innovative clinical trials, striving to advance healthcare solutions. Committed to research integrity and patient safety, they aim to improve outcomes and contribute to evidence-based medicine’s future. Their passion lies in making a meaningful healthcare impact, one study at a time.

Please note:
Due to the COVID-19 pandemic, the researchers would like to assure the participants that ensuring their and the study staff’s safety is of utmost importance.